Clofibrate-induced muscle damage in patients with chronic renal failure.
Muscle weakness and tenderness together with a rise in serum creatine kinase (C.K.) were noted in five uraemic patients treated with 1-2 g of clofibrate ('Atromid-S') daily. Excessive accumulation of both total and free serum chlorophenoxyisobutyric acid (C.P.I.B.), the active circulating metabolite after clofibrate therapy, was found in three patients in whom it was sought. It is suggested that chronic renal failure should be regarded as a contraindication to the use of clofibrate for the treatment of any coexisting hyperlipidaemia. If such therapy is contemplated it must be cautiously instituted at low dosage and the patient monitored by regular assessment of serum C.K. and levels of both total and free C.P.I.B.
D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D002087:Butyrates / Q000097:blood; D002784:Cholesterol / Q000097:blood; D002994:Clofibrate / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D003402:Creatine Kinase / Q000097:blood; D003404:Creatinine / Q000097:blood; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy; D007676:Kidney Failure, Chronic / Q000097:blood / Q000150:complications*; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008297:Male; D008875:Middle Aged; D009135:Muscular Diseases / Q000139:chemically induced*; D014280:Triglycerides / Q000097:blood; D014508:Urea / Q000097:blood
D002087:Butyrates; D014280:Triglycerides; D014508:Urea; D002784:Cholesterol; D003404:Creatinine; D007770:L-Lactate Dehydrogenase; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D003402:Creatine Kinase; D002994:Clofibrate